PLRZ

Polyrizon Ltd

• TipRanks·10/05 20:27

  Polyrizon Expands IP Moat With New U.S. Patent Filing for Intranasal Drug-Delivery Platform

• Benzinga·10/05 11:34

  Polyrizon Files New US Divisional Patent Application With USPTO, Further Expanding Its IP Portfolio Relating To Proprietary Mucoadhesive Technology

• TipRanks·09/28 20:58

  Polyrizon Files First-Half 2026 Results Showing Higher Assets and Wider Loss

• Seeking Alpha·09/28 20:26

  Polyrizon Ltd. GAAP EPS of -$0.79

• TipRanks·09/22 12:50

  Polyrizon enrolls first patient in U.S. study of NASARIX

• Benzinga·09/22 12:34

  Polyrizon Enrolls First Patient In U.S. NASARIX Allergy Blocker Trial, Entering Clinical Stage

• TipRanks·09/18 20:35

  Polyrizon files to sell 404,166 ordinary shares for holders

• TipRanks·09/04 14:57

  Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement

• NASDAQ·09/03 16:20

  Polyrizon Announces $4 Mln Registered Direct Offering And Private Placement

• Seeking Alpha·09/03 13:13

  Polyrizon prices $4M registered direct offering

• TipRanks·09/03 12:55

  Polyrizon announces $4.0M registered direct offering

• NASDAQ·09/02 14:35

  Polyrizon Completes Clinical Site Contracting For NASARIX Trial; Advances Into FIH Study Execution

• TipRanks·09/02 13:16

  Polyrizon completes all five U.S. site contracts for Nasarix allergy study

• Benzinga·08/31 17:06

  12 Health Care Stocks Moving In Monday's Intraday Session

• TipRanks·08/20 20:28

  Polyrizon Finalizes U.S. Clinical Site Network for NASARIX Allergy Study